The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFLX.L Regulatory News (FLX)

  • There is currently no data for FLX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Equity

14 Nov 2018 07:42

RNS Number : 3016H
Falanx Group Limited
14 November 2018
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Falanx Group Limited

("Falanx" or "the Company")

Issue of Equity

 

Falanx Group (AIM: FLX) ("Falanx" or "the Group" or "the Company" announces that on 14th of November 2018, the Company has issued 138,500,000 new ordinary shares of no par value in the capital of the Company ("Ordinary Shares") due to institutional demand ("the Subscription"). The Subscription has raised gross proceeds of £4,155,000 at a price of 3 pence per share.

 

This Subscription is almost entirely comprised of new institutional investors, including Miton Asset Management and Amati Global Investors. The proceeds will enable the Company to:

 

· Invest in delivery capabilities around a larger scale deployment into the SolarWinds customer base, by financing the additional sales, marketing, operations staff and required corporate infrastructure. This will include further technology investment, application rollout and Security Operations Centre expansion, to seamlessly handle much larger volumes;

 

· Address and accelerate incremental sales opportunities across the whole Group;

 

· Increase customer and partner confidence due to a significantly strengthened balance sheet;

 

· Provide (through non EIS/VCT monies) funding for opportunistic but earnings enhancing acquisitions.

 

Building on the progress detailed in the interim results for the six months ended 30 September 2018 released earlier today, the proceeds of the Subscription will allow the Company to undertake certain incremental initiatives of both a capital and operational nature. This will assist the business to drive and accelerate incremental returns over future periods and these are now expected to be greater than those originally envisaged.

 

Save for the routine issuance of shares under option and for warrant agreements for the incentivisation of staff, the Company does not expect to be issuing further equity save for a major incremental value creating project or earnings enhancing acquisitions.

 

Mike Read, Chairman and Chief Executive, commented;

 

"I am delighted the strength of our business and our future opportunities has attracted several new institutional investors, who have provided Falanx with a strong capital base for the future. This new support will enable the Group to grow in a rapidly expanding market, creating increased value for all our shareholders"

 

Total Voting Rights and Admission

 

Application will be made to the London Stock Exchange for the Subscription Shares to be admitted to trading on AIM ("Admission"). The Subscription Shares will rank pari passu in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions declared, made or paid in respect of the Ordinary Shares following Admission. It is expected that Admission will become effective, and that dealings on AIM will commence on or around, 8.00 a.m. on 20 November 2018.

 

Following Admission, the Company will have 400,401,186 Ordinary Shares in issue. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares with voting rights in the Company will be 400,401,186. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules sourcebook.

 

 

Enquiries:

 

 

Falanx Group Limited

Mike Read, Chief Executive Officer

 

www.falanx.com

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis / James Keeshan

+44 (0) 203 368 3551

 

 

 

 

 

Turner Pope Investments (TPI) Ltd

Broker

Ben Turner / James Pope

 

IFC Advisory Ltd

Financial PR & IR

Graham Herring

Miles Nolan

Zach Cohen

+44 (0) 203 621 4120

 

 

 

+44 (0) 203 934 6630

 

     

 

About Falanx

Falanx Group Limited, is a global intelligence and cyber defence provider working with blue chip and government clients. It operates the MidGARD cyber monitoring platform for corporate and governmental customers which utilises a combination of proprietary and third-party processes and technologies. For more information: http://www.falanx.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEDZLBFVFFXFBK
Date   Source Headline
9th Dec 20222:42 pmRNSHolding(s) in Company
8th Dec 20224:29 pmRNSResult of AGM
8th Dec 20227:00 amRNSInterim Results
24th Nov 20225:17 pmRNSHolding(s) in Company
15th Nov 20225:56 pmRNSNotice of AGM
18th Oct 20227:00 amRNSDirectorate Change
29th Sep 20227:00 amRNSFinal Results
20th Sep 20227:00 amRNSHolding(s) in Company
5th Sep 20224:53 pmRNSHolding(s) in Company
4th Aug 20222:06 pmRNSSecond Price Monitoring Extn
4th Aug 20222:00 pmRNSPrice Monitoring Extension
4th Aug 202211:05 amRNSSecond Price Monitoring Extn
4th Aug 202211:00 amRNSPrice Monitoring Extension
4th Aug 20227:00 amRNSTrading Update
9th May 20227:00 amRNSPartnership to Provide M-EDR to UK Customers
8th Apr 20224:06 pmRNSHolding(s) in Company
6th Apr 202211:59 amRNSHolding(s) in Company
1st Apr 20227:00 amRNSChange of Adviser
30th Mar 20222:44 pmRNSDirector/PDMR Shareholding
23rd Mar 202212:59 pmRNSDirector/PDMR Shareholding
10th Feb 202211:11 amRNSDirector/PDMR Shareholding
24th Jan 20227:00 amRNSDirector/PDMR Shareholding
19th Jan 20225:20 pmRNSHolding(s) in Company
19th Jan 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 202111:14 amRNSResult of AGM
7th Dec 20217:00 amRNSInterim Results
16th Nov 20212:10 pmRNSNotice of AGM
29th Oct 20211:57 pmRNSExercise of Options, TVR and PDMR dealing
27th Oct 20219:03 amRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSDirector/PDMR Shareholding
25th Oct 20213:25 pmRNSExercise of Options and TVR
13th Oct 202111:06 amRNSSecond Price Monitoring Extn
13th Oct 202111:00 amRNSPrice Monitoring Extension
13th Oct 20217:00 amRNSTrading update and BOOST&Co loan facility update
6th Oct 20214:41 pmRNSSecond Price Monitoring Extn
6th Oct 20214:35 pmRNSPrice Monitoring Extension
6th Oct 20212:43 pmRNSSale of Assynt for £4.6 million
4th Oct 20217:00 amRNSFalanx Launch Mass Market Security Assessment Tool
29th Sep 20217:00 amRNSAnnual results for the year ended 31 March 2021
18th Aug 20217:01 amRNSGrant of share options
18th Aug 20217:00 amRNSTrading Update & New Loan Facility
9th Jul 20219:07 amRNSHolding(s) in Company
29th Apr 20217:00 amRNSCancellation of unapproved Share Options
1st Apr 20217:00 amRNSIssue of Equity and TVR
26th Feb 20213:31 pmRNSResult of GM
10th Feb 20212:03 pmRNSPublication of Circular & Notice of GM
8th Feb 202111:05 amRNSSecond Price Monitoring Extn
8th Feb 202111:00 amRNSPrice Monitoring Extension
5th Feb 20217:00 amRNSContract Wins and Covid Business Interruption Loan
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.